However, further research is needed to evaluate the impact of neoadjuvant treatment on NANOG expression in esophageal adenocarcinoma—especially dependent on the difference between chemotherapy versus chemoradiotherapy [26, 27]. The gene discussed is NANOG; the disease is esophageal adenocarcinoma.